Ark Biotech
Develops bioreactors for the industrial production of cultivated meat.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $8.2m | Early VC |
| Total Funding | 000k | ||
Related Content
Ark Biotech specializes in creating cost-effective bioreactors designed for the large-scale production of cultivated meat. Operating within the sustainable food technology sector, Ark Biotech serves companies aiming to produce meat through cell culture rather than traditional livestock farming. The business model revolves around the sale and deployment of bioreactors, which are essential for the industrial-scale cultivation of meat cells. Revenue is generated through the sale of these bioreactors and potentially through long-term service agreements for maintenance and support. Ark Biotech is addressing a significant market demand, with projections indicating a need for 250 million liters of bioreactor capacity by 2025 and 1 billion liters by 2030. The company is at the forefront of transforming protein consumption by providing the necessary infrastructure to scale cultivated meat production, thereby benefiting both the planet and its inhabitants.
Keywords: bioreactors, cultivated meat, sustainable protein, industrial-scale, cell culture, food technology, infrastructure, market demand, innovation, scalable solutions.